Xconomy | San Diego - Business + Technology in the Exponential Economy

Sequenom Makes Takeover Bid for MA-Based Exact Sciences, Targets Test for Colorectal Cancer
Sequenom Ousts CEO Harry Stylli, After Investigating Mishandling of Down Syndrome Test
Sequenom May Spot Single-Gene Birth Defects, like Cystic Fibrosis, in a Sample of Mother’s Blood
Sequenom Blood Test for Down’s Syndrome Clears Higher Hurdle, Company Plots Aggressive Moves Toward Market
Sequenom Getting Aggressive in Bid to Buy Exact Sciences

Sequenom Buys Small Diagnostic Maker

Sequenom, the San Diego-based developer of a non-invasive prenatal test for Down Syndrome, said today it has acquired Ann Arbor, MI-based SensiGen for $8.7 million, plus potential milestones. The deal gives Sequenom (NASDAQ: SQNM) molecular diagnostics for human papillomavirus, lupus, chronic kidney disease, and inflammatory bowel disease. The purchase is part of Sequenom’s strategy to offer diagnostics for women’s health and cancer, CEO Harry Stylli said in a statement.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: